Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis
Autor: | Viktoriya L Nikolova, Roxanna Short, Lindsey Marwood, Dimosthenis Tsapekos, Muhammad Ishrat Husain, André F. Carvalho, Fiona Patrick, Rebecca Strawbridge, Anthony J. Cleare, Ben Carter, Valeria de Angel, Tim Mantingh, Allan H. Young, Rachael W. Taylor, Brett D.M. Jones |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
business.industry Network Meta-Analysis Psychological intervention medicine.disease 030227 psychiatry 03 medical and health sciences Psychiatry and Mental health Depressive Disorder Treatment-Resistant 0302 clinical medicine Treatment Outcome Mood stabilisers Meta-analysis medicine Humans business Psychiatry Treatment-resistant depression 030217 neurology & neurosurgery Depression (differential diagnoses) Antipsychotic Agents |
Zdroj: | International review of psychiatry (Abingdon, England). 32(5-6) |
ISSN: | 1369-1627 |
Popis: | Most interventions for treatment-resistant depression (TRD) are added as augmenters. We aimed to determine the relative effectiveness of augmentation treatments for TRD. This systematic review and network meta-analysis (NMA) sought all randomized trials of pharmacological and psychological augmentation interventions for adults meeting the most common clinical criteria for TRD. The NMA compared the intervention effectiveness of depressive symptoms for TRD augmentation. Of 36 included trials, 27 were suitable for inclusion in NMA, and no psychological trials could be included in the absence of a common comparator. Antipsychotics (13 trials), mood stabilizers (three trials), NMDA-targeting medications (five trials), and other mechanisms (3 trials) were compared against placebo. NMDA treatments were markedly superior to placebo (ES = 0.91, 95% CI 0.67 to 1.16) and head-to-head NMA suggested that NMDA therapies had the highest chance of being an effective treatment option compared to other pharmacological classes. This study provides the most comprehensive evidence of augmenters' effectiveness for TRD, and our GRADE recommendations can be used to guide guidelines to optimize treatment choices. Although conclusions are limited by paucity of, and heterogeneity between, trials as well as inconsistent reports of treatment safety. This work supports the use of NMDA-targeting medications such as ketamine. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |